IMMUNI T inception was not fortuitous. Following a PhD training in experimental medicine at McGill University and several years of research in academic settings, I had the opportunity to migrate to the private sector, where I first acted as CSO of a biotech company developing new compounds for cancer treatments. 

After successful discovery steps, a new molecule, di-bromo rhodamine 123 was evaluated as an ex vivo anti-cancer treatment, in autologous or allogeneic bone marrow and PBMC transfer protocols. It would specifically eliminate cells with cancerous behavior, sparing all precious and healthy stem cells.. This experimental readiness and expertise was put to use through the inception of a new contract research organization: IMMUNI T in 2005. Since then, we never looked back and our efforts at providing support to biotherapeutics developers have concentrated on providing primary human cell test systems, for results that are meaningful and that significantely reduce the possibility of failure down the line, in clinical phase 3 and phase 4 deployment.
Overall at IMMUNI T we have time after time not only respected our sponsors’ projects timelines, but also provided full transparency of our operations, essential for optimal team work as our main goal is helping patients by improving their quality of life.